Zurück zu Projekte

18929.1 PFLS-LS

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Zusammenfassung

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Weitere Texte

Abstract

The use of recombinant antibodies as delivery vehicles promises to greatly enhance the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. However, current generation immunocytokines do not elicit cures in vivo whereas combination immunocytokine therapies can. This project aims to develop 'second generation' immunocytokines to capitalize on this observation by combining synergistic cytokine pairs into a single therapeutic molecule

Beteiligte

Catherine Hutchinson

Wirtschaftspartner

catherine.hutchinson@philochem.ch

Philochem AG CHE-113.181.443 Catherine Hutchinson Libernstrasse 3 8112 Otelfingen ZH CH

Dario Neri

Kontaktperson

dario.neri@pharma.ethz.ch

ETH Zürich Inst. of Pharmac. Sciences Dario Neri HCI G496 / Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2016-08-31
Enddatum
2017-08-31
Bewilligte Gesamtkosten
CHF 55814.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%